expresspharmaApril 01, 2021
Tag: GSK , Vemgal , Hetero Labs
GlaxoSmithKline Pharmaceuticals said its board has approved the sale of its manufacturing facility located at Vemgal in Karnataka to Hetero Labs for a consideration of Rs 180 crores.
The board of directors “approved the sale of the company’s business undertaking i.e., manufacturing facility together with the land, plant and machinery, assets, software and equipment located at Vemgal, Karnataka, to Hetero Labs Ltd,” the company said in a regulatory filing.
The transaction is expected to be completed by September 30, 2021, it added.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: